Healthcare / BiotechnologyShenzhen
$28.44
+0.19 (+0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-43.6M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1.1%
↓Gross Margin
18.8%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.2%
FCF CAGR
—
FCF margin
-4.0%
FCF / Net income
1.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.08B · net income $-22.9M · FCF $-43.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.08B | $1.08B | $1.12B | $1.23B | $1.20B |
| Net Income | $-22.9M | $-22.9M | $10.1M | $40.3M | $106.6M |
| EBITDA | $-7.4M | $-7.4M | $24.3M | $56.4M | $141.5M |
| EPS | -0.26 | -0.26 | 0.12 | 0.47 | 1.23 |
| Gross Margin | 18.8% | 18.8% | 18.1% | 19.6% | 22.3% |
| Operating Margin | -3.9% | -3.9% | -2.3% | 1.3% | 8.8% |
| Net Margin | -2.1% | -2.1% | 0.9% | 3.3% | 8.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | 0.01 | 0.05 |
| Current Ratio | 6.47 | 6.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-43.6M | $-43.6M | $4.8M | $-85.9M | $-204.8M |
| Returns | |||||
| ROE | -1.1% | -1.1% | 0.5% | 1.9% | 4.9% |
| Valuation | |||||
| P/E | — | — | 223.33 | 80.26 | 38.63 |
| EV/EBITDA | — | — | 59.51 | 50.42 | 24.66 |
| P/B | 1.25 | 1.25 | 1.10 | 1.53 | 1.91 |
| Growth & Yield | |||||
| Revenue Growth | -3.0% | -3.0% | -8.8% | 2.6% | — |
| EPS Growth | -316.7% | -316.7% | -74.5% | -61.8% | — |
| Dividend Yield | 2.1% | 2.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.12 → -0.26
Residual
-3.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.